Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Head and Neck Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 89 articles: HTML format

Single Articles

March 2024
1. HIRAI R, Kinugasa H, Yamamoto S, Ako S, et al
   Methylation analysis of DCC gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer.
   Br J Cancer. 2024 Mar 27. doi: 10.1038/s41416-024-02654.
   PubMed     Abstract available
   
   
   
2. XU J, Chen D, Wu W, Ji X, et al
   A metabolic map and artificial intelligence-aided identification of nasopharyngeal carcinoma via a single-cell Raman platform.
   Br J Cancer. 2024 Mar 7. doi: 10.1038/s41416-024-02637.
   PubMed     Abstract available
   
   
   
3. SHANG Q, Jiang Y, Wan Z, Peng J, et al
   The clinical implication and translational research of OSCC differentiation.
   Br J Cancer. 2024;130:660-670.
   PubMed     Abstract available
   
   
   
4. CHENG Z, Johar A, Nilsson M, Schandl A, et al
   Cancer-related fatigue trajectories up to 5 years after curative treatment for oesophageal cancer.
   Br J Cancer. 2024;130:628-637.
   PubMed     Abstract available
   
   
   February 2024
5. CECCHINI M, Cleary JM, Shyr Y, Chao J, et al
   NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
   Br J Cancer. 2024;130:476-482.
   PubMed     Abstract available
   
   
   
6. JAVED SR, Lord S, El Badri S, Harman R, et al
   CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
   Br J Cancer. 2024;130:467-475.
   PubMed     Abstract available
   
   
   January 2024
7. LIN W, Chen X, Huang Z, Ding Q, et al
   Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma.
   Br J Cancer. 2024 Jan 27. doi: 10.1038/s41416-024-02579.
   PubMed     Abstract available
   
   
   
8. LI G, Wang H, Zhong J, Bai Y, et al
   Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study.
   Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-024-02575.
   PubMed     Abstract available
   
   
   
9. CHEN Y, Feng Y, Lin Y, Zhou X, et al
   GSTM3 enhances radiosensitivity of nasopharyngeal carcinoma by promoting radiation-induced ferroptosis through USP14/FASN axis and GPX4.
   Br J Cancer. 2024 Jan 16. doi: 10.1038/s41416-024-02574.
   PubMed     Abstract available
   
   
   
10. STOGBAUER F, Beck S, Ourailidis I, Hess J, et al
    Correction: Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.
    Br J Cancer. 2024 Jan 8. doi: 10.1038/s41416-023-02521.
    PubMed    
    
    
    
11. HUANG Q, Liu Z, Yu Y, Rong Z, et al
    Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test.
    Br J Cancer. 2024 Jan 4. doi: 10.1038/s41416-023-02547.
    PubMed     Abstract available
    
    
    
12. CLEMENTS HA, Underwood TJ, Petty RD
    Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma.
    Br J Cancer. 2024;130:9-18.
    PubMed     Abstract available
    
    
    December 2023
13. ALMANGUSH A, Makitie AA, Leivo I
    Tumour budding in head and neck cancer: what have we learnt and the next steps towards clinical implementation.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02531.
    PubMed    
    
    
    
14. SARODE G, Sarode SC
    Comment on "Development and validation of a multivariable model for prediction of malignant transformation and recurrence of oral epithelial dysplasia".
    Br J Cancer. 2023;129:1875-1876.
    PubMed    
    
    
    November 2023
15. MAHMOOD H, Shephard A, Hankinson P, Bradburn M, et al
    Development and validation of a multivariable model for prediction of malignant transformation and recurrence of oral epithelial dysplasia.
    Br J Cancer. 2023;129:1599-1607.
    PubMed     Abstract available
    
    
    
16. MENG X, Zheng A, Wang J, Wu X, et al
    Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.
    Br J Cancer. 2023;129:1787-1792.
    PubMed     Abstract available
    
    
    
17. TOWLE R, Dickman CTD, MacLellan SA, Chen J, et al
    Identification of a serum-based microRNA signature that detects recurrent oral squamous cell carcinoma before it is clinically evident.
    Br J Cancer. 2023;129:1810-1817.
    PubMed     Abstract available
    
    
    October 2023
18. LIU JY, Yu ZL, Fu QY, Zhang LZ, et al
    Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.
    Br J Cancer. 2023;129:925-934.
    PubMed     Abstract available
    
    
    September 2023
19. PAYNE K, Brooks J, Batis N, Khan N, et al
    Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.
    Br J Cancer. 2023 Sep 21. doi: 10.1038/s41416-023-02428.
    PubMed     Abstract available
    
    
    
20. YI H, Lin Y, Wang X, Mao Y, et al
    Pan-cancer analysis of TRPV2 identifies its potential role as a prognostic and immunologic biomarker in oesophageal cancer.
    Br J Cancer. 2023;129:567-569.
    PubMed    
    
    
    August 2023
21. NAKAMURA S, Ohuchida K, Hayashi M, Katayama N, et al
    Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma.
    Br J Cancer. 2023 Aug 21. doi: 10.1038/s41416-023-02396.
    PubMed     Abstract available
    
    
    July 2023
22. BERNER J, Miebach L, Kordt M, Seebauer C, et al
    Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo.
    Br J Cancer. 2023 Jul 17. doi: 10.1038/s41416-023-02343.
    PubMed     Abstract available
    
    
    June 2023
23. YU W, Chen Y, Putluri N, Osman A, et al
    Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
    Br J Cancer. 2023;128:2013-2024.
    PubMed     Abstract available
    
    
    
24. DAMANAKIS AI, Gebauer F, Stapper A, Schlosser HA, et al
    Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer.
    Br J Cancer. 2023;128:2025-2035.
    PubMed     Abstract available
    
    
    
25. HAYASHI Y, Makino T, Sato E, Ohshima K, et al
    Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.
    Br J Cancer. 2023;128:2175-2185.
    PubMed     Abstract available
    
    
    May 2023
26. APRILE M, Cataldi S, Perfetto C, Federico A, et al
    Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1alpha-mediated glycolytic phenotype.
    Br J Cancer. 2023 May 17. doi: 10.1038/s41416-023-02282.
    PubMed     Abstract available
    
    
    
27. YAMASAKI M, Miyata H, Yamashita K, Hamakawa T, et al
    Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer: survival results from a multicenter randomized Phase 2 trial.
    Br J Cancer. 2023 May 4. doi: 10.1038/s41416-023-02286.
    PubMed     Abstract available
    
    
    
28. MUHLENBRUCH L, Abou-Kors T, Dubbelaar ML, Bichmann L, et al
    The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
    Br J Cancer. 2023;128:1777-1787.
    PubMed     Abstract available
    
    
    
29. NOSE Y, Makino T, Tatsumi M, Tanaka K, et al
    Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes.
    Br J Cancer. 2023;128:1879-1887.
    PubMed     Abstract available
    
    
    April 2023
30. STOGBAUER F, Beck S, Ourailidis I, Hess J, et al
    Tumour budding-based grading as independent prognostic biomarker in HPV-positive and HPV-negative head and neck cancer.
    Br J Cancer. 2023 Apr 12. doi: 10.1038/s41416-023-02240.
    PubMed     Abstract available
    
    
    
31. KOSUMI K, Baba Y, Yamamura K, Nomoto D, et al
    Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer.
    Br J Cancer. 2023;128:1155-1165.
    PubMed     Abstract available
    
    
    March 2023
32. MAO L, Zhou JJ, Xiao Y, Yang QC, et al
    Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner.
    Br J Cancer. 2023 Mar 28. doi: 10.1038/s41416-023-02230.
    PubMed     Abstract available
    
    
    
33. ZHAO M, He Y, Zhu N, Song Y, et al
    IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
    Br J Cancer. 2023;128:833-843.
    PubMed     Abstract available
    
    
    
34. PISULA JI, Datta RR, Valdez LB, Avemarg JR, et al
    Predicting the HER2 status in oesophageal cancer from tissue microarrays using convolutional neural networks.
    Br J Cancer. 2023;128:1369-1376.
    PubMed     Abstract available
    
    
    
35. WANG Y, Du J, Gao Z, Sun H, et al
    Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.
    Br J Cancer. 2023;128:1196-1207.
    PubMed     Abstract available
    
    
    February 2023
36. LUDWIG N, Yerneni SS, Harasymczuk M, Szczepanski MJ, et al
    TGFbeta carrying exosomes in plasma: potential biomarkers of cancer progression in patients with head and neck squamous cell carcinoma.
    Br J Cancer. 2023 Feb 21. doi: 10.1038/s41416-023-02184.
    PubMed     Abstract available
    
    
    
37. CHAVES P, Garrido M, Oliver J, Perez-Ruiz E, et al
    Preclinical models in head and neck squamous cell carcinoma.
    Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02186.
    PubMed     Abstract available
    
    
    
38. BASNAYAKE BWMTJ, Leo P, Rao S, Vasani S, et al
    Head and neck cancer patient-derived tumouroid cultures: opportunities and challenges.
    Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02167.
    PubMed     Abstract available
    
    
    
39. LAWRIE CH
    Progress in the blood-based diagnosis of oesophageal squamous cell carcinoma (ESCC) using microRNAs: Comment on Komatsu et al. (BJC (2011) 105, 104-111).
    Br J Cancer. 2023;128:446-447.
    PubMed    
    
    
    December 2022
40. KO JM, Guo C, Liu C, Ning L, et al
    Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma.
    Br J Cancer. 2022;127:2166-2174.
    PubMed     Abstract available
    
    
    
41. CABEZA-SEGURA M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, et al
    Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma.
    Br J Cancer. 2022;127:2198-2206.
    PubMed     Abstract available
    
    
    November 2022
42. SUNGUC C, Hawkins MM, Winter DL, Dudley IM, et al
    Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02016.
    PubMed     Abstract available
    
    
    
43. XUE L, Zhao Z, Wang M, Ma L, et al
    A liquid biopsy signature predicts lymph node metastases in T1 oesophageal squamous cell carcinoma: implications for precision treatment strategy.
    Br J Cancer. 2022;127:2052-2059.
    PubMed     Abstract available
    
    
    
44. ZAIDI AH, Pratama MY, Omstead AN, Gorbonova A, et al
    A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma.
    Br J Cancer. 2022;127:2016-2024.
    PubMed     Abstract available
    
    
    October 2022
45. TRAN TV, Rubino C, Allodji R, Andruccioli M, et al
    Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
    Br J Cancer. 2022 Oct 12. pii: 10.1038/s41416-022-01982.
    PubMed     Abstract available
    
    
    September 2022
46. ANDERSON K, Ryan N, Nedungadi D, Lamenza F, et al
    STAT1 is regulated by TRIM24 and promotes immunosuppression in head and neck squamous carcinoma cells, but enhances T cell antitumour immunity in the tumour microenvironment.
    Br J Cancer. 2022;127:624-636.
    PubMed     Abstract available
    
    
    August 2022
47. CAINI S, Del Riccio M, Vettori V, D'Ecclesiis O, et al
    Post-diagnosis smoking cessation and survival of patients with head and neck cancer: a systematic review and meta-analysis.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01945.
    PubMed     Abstract available
    
    
    
48. ROSENBERG AJ, Agrawal N, Pearson AT, Gooi Z, et al
    Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma.
    Br J Cancer. 2022 Aug 9. pii: 10.1038/s41416-022-01941.
    PubMed     Abstract available
    
    
    
49. TANG K, Toyozumi T, Murakami K, Sakata H, et al
    HIF-1alpha stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/beta-catenin signalling pathway.
    Br J Cancer. 2022;127:474-487.
    PubMed     Abstract available
    
    
    
50. LI X, Jiang E, Zhao H, Chen Y, et al
    Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: role of PGC-1alpha/PFKFB3 axis.
    Br J Cancer. 2022;127:449-461.
    PubMed     Abstract available
    
    
    July 2022
51. HUANG R, Li S, Tian C, Zhou P, et al
    Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma.
    Br J Cancer. 2022 Jul 27. pii: 10.1038/s41416-022-01896.
    PubMed     Abstract available
    
    
    
52. XIE T, Du K, Liu W, Liu C, et al
    LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis.
    Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01902.
    PubMed     Abstract available
    
    
    June 2022
53. MASUKUME G, Mmbaga BT, Dzamalala CP, Mlombe YB, et al
    A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case-control studies.
    Br J Cancer. 2022 Jun 29. pii: 10.1038/s41416-022-01890.
    PubMed     Abstract available
    
    
    
54. RABBANI S, Santoni G, Lagergren J, Xie SH, et al
    Use of anti-androgenic 5alpha-reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site.
    Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01872.
    PubMed     Abstract available
    
    
    
55. MAKINO T, Yamasaki M, Tanaka K, Yamashita K, et al
    Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma.
    Br J Cancer. 2022;126:1555-1562.
    PubMed     Abstract available
    
    
    
56. ALMANGUSH A, Jouhi L, Atula T, Haglund C, et al
    Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.
    Br J Cancer. 2022;126:1589-1594.
    PubMed     Abstract available
    
    
    March 2022
57. BOLGER JC, Donohoe CL, Lowery M, Reynolds JV, et al
    Advances in the curative management of oesophageal cancer.
    Br J Cancer. 2022;126:706-717.
    PubMed     Abstract available
    
    
    
58. ANDREW TW, Hamnett N, Roy I, Garioch J, et al
    Machine-learning algorithm to predict multidisciplinary team treatment recommendations in the management of basal cell carcinoma.
    Br J Cancer. 2022;126:562-568.
    PubMed     Abstract available
    
    
    February 2022
59. PATEL U, Kannan S, Rane SU, Mittal N, et al
    Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab.
    Br J Cancer. 2022 Feb 9. pii: 10.1038/s41416-022-01730.
    PubMed     Abstract available
    
    
    
60. FLACH S, Howarth K, Hackinger S, Pipinikas C, et al
    Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
    Br J Cancer. 2022 Feb 7. pii: 10.1038/s41416-022-01716.
    PubMed     Abstract available
    
    
    January 2022
61. SCHACK LMH, Naderi E, Fachal L, Dorling L, et al
    A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis.
    Br J Cancer. 2022 Jan 17. pii: 10.1038/s41416-021-01670.
    PubMed     Abstract available
    
    
    December 2021
62. HUTCHISON IL, Ridout F, Cheung SMY, Shah N, et al
    Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.
    Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01678.
    PubMed    
    
    
    
63. WEI Y, Wu W, Jiang Y, Zhou H, et al
    Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4.
    Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01651.
    PubMed     Abstract available
    
    
    
64. MISHRA V, Singh A, Chen X, Rosenberg AJ, et al
    Application of liquid biopsy as multi-functional biomarkers in head and neck cancer.
    Br J Cancer. 2021 Dec 7. pii: 10.1038/s41416-021-01626.
    PubMed     Abstract available
    
    
    November 2021
65. KOBAYASHI T, Makino T, Yamashita K, Saito T, et al
    APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
    Br J Cancer. 2021;125:1523-1532.
    PubMed     Abstract available
    
    
    October 2021
66. XIE SH, Santoni G, Lagergren J
    Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
    Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01575.
    PubMed     Abstract available
    
    
    
67. THEODORAKI MN, Laban S, Jackson EK, Lotfi R, et al
    Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients.
    Br J Cancer. 2021 Oct 12. pii: 10.1038/s41416-021-01567.
    PubMed     Abstract available
    
    
    
68. BOUROVA-FLIN E, Derakhshan S, Goudarzi A, Wang T, et al
    The combined detection of Amphiregulin, Cyclin A1 and DDX20/Gemin3 expression predicts aggressive forms of oral squamous cell carcinoma.
    Br J Cancer. 2021;125:1122-1134.
    PubMed     Abstract available
    
    
    
69. BAXTER MA, Middleton F, Cagney HP, Petty RD, et al
    Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.
    Br J Cancer. 2021;125:1068-1079.
    PubMed     Abstract available
    
    
    
70. DE PAULA B, C Smyth E
    Personalising care in oesophageal cancer care with liquid biopsy.
    Br J Cancer. 2021;125:1036-1038.
    PubMed     Abstract available
    
    
    September 2021
71. ZOU Z, Zheng W, Fan H, Deng G, et al
    Aspirin enhances the therapeutic efficacy of cisplatin in oesophageal squamous cell carcinoma by inhibition of putative cancer stem cells.
    Br J Cancer. 2021;125:826-838.
    PubMed     Abstract available
    
    
    August 2021
72. LIANG J, Jin Z, Kuang J, Feng H, et al
    The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
    Br J Cancer. 2021;125:390-401.
    PubMed     Abstract available
    
    
    
73. GAO S, Liu Y, Duan X, Liu K, et al
    Porphyromonas gingivalis infection exacerbates oesophageal cancer and promotes resistance to neoadjuvant chemotherapy.
    Br J Cancer. 2021;125:433-444.
    PubMed     Abstract available
    
    
    
74. SATHASIVAM HP, Kist R, Sloan P, Thomson P, et al
    Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology.
    Br J Cancer. 2021;125:413-421.
    PubMed     Abstract available
    
    
    
75. YUAN Y, Zhao Z, Xue L, Wang G, et al
    Identification of diagnostic markers and lipid dysregulation in oesophageal squamous cell carcinoma through lipidomic analysis and machine learning.
    Br J Cancer. 2021;125:351-357.
    PubMed     Abstract available
    
    
    
76. DAVERN M, Donlon NE, Power R, Hayes C, et al
    The tumour immune microenvironment in oesophageal cancer.
    Br J Cancer. 2021;125:479-494.
    PubMed     Abstract available
    
    
    July 2021
77. WU P, Xie C, Yang L, Liu Y, et al
    The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
    Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01464.
    PubMed     Abstract available
    
    
    June 2021
78. SULKSHANE P, Pawar SN, Waghole R, Pawar SS, et al
    Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabilisation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers.
    Br J Cancer. 2021 Jun 2. pii: 10.1038/s41416-021-01421.
    PubMed     Abstract available
    
    
    
79. ZOLGHADR F, Tse N, Loka D, Joun G, et al
    A Wnt-mediated phenotype switch along the epithelial-mesenchymal axis defines resistance and invasion downstream of ionising radiation in oral squamous cell carcinoma.
    Br J Cancer. 2021;124:1921-1933.
    PubMed     Abstract available
    
    
    
80. SHRIWAS O, Arya R, Mohanty S, Mohapatra P, et al
    RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway.
    Br J Cancer. 2021;124:2004-2016.
    PubMed     Abstract available
    
    
    May 2021
81. JENSEN KH, Vogelius I, Moser CE, Andersen E, et al
    Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database.
    Br J Cancer. 2021 May 20. pii: 10.1038/s41416-021-01430.
    PubMed     Abstract available
    
    
    
82. KNIGHT WRC, Baker CR, Griffin N, Wulaningsih W, et al
    Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
    Br J Cancer. 2021;124:1653-1660.
    PubMed     Abstract available
    
    
    April 2021
83. MAHMOOD H, Shaban M, Rajpoot N, Khurram SA, et al
    Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview.
    Br J Cancer. 2021 Apr 19. pii: 10.1038/s41416-021-01386.
    PubMed     Abstract available
    
    
    March 2021
84. OLIVA M, Schneeberger PHH, Rey V, Cho M, et al
    Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
    Br J Cancer. 2021 Mar 10. pii: 10.1038/s41416-020-01253.
    PubMed     Abstract available
    
    
    
85. LIU Y, Baba Y, Ishimoto T, Tsutsuki H, et al
    Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma.
    Br J Cancer. 2021;124:963-974.
    PubMed     Abstract available
    
    
    February 2021
86. NG SP, Bahig H, Jethanandani A, Sturgis EM, et al
    Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy.
    Br J Cancer. 2021;124:628-633.
    PubMed     Abstract available
    
    
    
87. KILLCOYNE S, Fitzgerald RC
    Practical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues.
    Br J Cancer. 2021;124:683-685.
    PubMed     Abstract available
    
    
    December 2020
88. KIM HR, Kang HN, Yun MR, Ju KY, et al
    Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
    Br J Cancer. 2020;123:1720-1729.
    PubMed     Abstract available
    
    
    
89. PATEL U, Pandey M, Kannan S, Samant TA, et al
    Prognostic and predictive significance of nuclear HIF1alpha expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
    Br J Cancer. 2020;123:1757-1766.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.